5014 completed, 885 unknown, 802 terminated, 444 recruiting. 7996 Phase 2, 1387 Phase 1, 917 Phase 3.
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart | Phase 2 | Suspended | G&E Herbal Biotechnology Co., LTD | 102 | 2030-09-01 | 2023-09-14 |
| Effects of Food Intake on Biomarker Activity in Normal Humans Taking Immulina Immulina, Placebo - Viral Diseases | Phase 2 | Not yet recruiting | University of Mississippi Medical Center | 250 | 2028-01-01 | 2026-10-23 |
| Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy | Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 120 | 2027-08-01 | 2026-08-20 |
| Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Moxifloxacin, Placebo - Endophthalmitis | Phase 2 / Phase 3 | Not yet recruiting | Jason Ahee, M.D. | 60000 | 2027-06-01 | 2026-09-15 |
| Topical Curcumin for HPV Related Cervical Disease Curcumin C3 Complex, Placebo - Neoplasm Cervix | Phase 2 | Not yet recruiting | Lisa Flowers | 200 | 2027-04-01 | 2026-05-08 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB ID93 + GLA-SE vaccine, Placebo vaccine - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 1500 | 2027-01-31 | 2026-08-24 |
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs ATRN-119, Stereotactic Body Radiation Therapy (SBRT) - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 35 | 2027-01-31 | 2026-10-27 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO Low anticoagulation dose of argatroban and enoxaparin during ECMO, Standard anticoagulation dose of argatroban and enoxaparin during ECMO - Pneumonia, Heart Failure | Phase 2 | Not yet recruiting | University Hospital Ostrava | 200 | 2027-01-01 | 2026-04-02 |
| Precision Modulation of Gut Microbiome Enteropathogen Colonization in Critical Illness Synbiotic, Standard of Care (SOC) - Critical Illness | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 64 | 2027-01-01 | 2026-09-10 |
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Ervebo, Inmazeb - Ebola Virus Disease | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 132 | 2027-01-01 | 2026-01-22 |
| Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis Para-Tyrosine supplementation, Placebo solution - Sepsis | Phase 2 | Suspended | University of Pecs | 296 | 2027-01-01 | 2025-03-30 |
| A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization Resistant Potato Starch, Maltodextrin - Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA) | Phase 2 | Not yet recruiting | VA Office of Research and Development | 120 | 2027-01-01 | 2026-08-28 |
| Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia colistimethate sodium, 0.9% Saline - Ventilator Associated Pneumonia | Phase 2 / Phase 3 | Not yet recruiting | University Hospital Fattouma Bourguiba | 400 | 2027-01-01 | 2026-10-08 |
| Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin Vancomycin (POC) - Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium | Phase 2 / Phase 3 | Withdrawn | University of Maryland, Baltimore | 2027-01-01 | 2026-07-29 | |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19 | Phase 1 / Phase 2 | Not yet recruiting | Kimera Labs Inc. | 64 | 2027-01-01 | 2026-06-24 |
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 |
Showing 20 of 7996. Sign in to see all of them.
COVID-19 (1391) · HIV Infections (919) · Influenza, Human (492) · Burkitt Lymphoma (419) · Acquired Immunodeficiency Syndrome (418) · Hepatitis C (339) · Coronavirus Infections (274) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (245) · Lymphoma, Large B-Cell, Diffuse (232) · Hepatitis C, Chronic (227) · Sepsis (227) · Lymphoma, Follicular (218) · Lymphoma (214) · Lymphoma, Non-Hodgkin (210)
Virus Diseases (5173) · RNA Virus Infections (4002) · Respiratory Tract Diseases (2615) · Respiratory Tract Infections (2409) · Communicable Diseases (2026) · Pathological Conditions, Signs and Symptoms (1963) · Lung Diseases (1925) · Blood-Borne Infections (1879) · Immune System Diseases (1799) · Pathologic Processes (1772) · Urogenital Diseases (1572) · Nidovirales Infections (1507) · Coronaviridae Infections (1506) · Pneumonia (1463)
Ribavirin (245) · Cyclophosphamide (157) · Saline Solution (143) · Ritonavir (138) · Sodium Chloride (137) · peginterferon alfa-2a (137) · Standard of Care (131) · Tenofovir (102) · Influenza Vaccines (100) · Rituximab (96) · Zidovudine (81) · Etoposide (79) · Lamivudine (73) · Hydroxychloroquine (72) · Methotrexate (70)
National Institute of Allergy and Infectious Diseases (NIAID) (485) · GlaxoSmithKline (283) · Merck Sharp & Dohme LLC (122) · Gilead Sciences (105) · Sanofi Pasteur, a Sanofi Company (97) · National Cancer Institute (NCI) (94) · Pfizer (89) · U.S. Army Medical Research and Development Command (65) · University of Oxford (64) · Novartis Vaccines (52) · M.D. Anderson Cancer Center (50) · Fred Hutchinson Cancer Center (49) · Bristol-Myers Squibb (48) · Novartis Pharmaceuticals (47) · ViiV Healthcare (42)
United States (3414) · Canada (534) · France (471) · China (460) · Germany (440) · Spain (421) · United Kingdom (419) · South Africa (340) · Italy (295) · Australia (289) · Brazil (274) · Belgium (255) · Puerto Rico (250) · Thailand (194) · South Korea (193)
Mike Royal, MD (14)
PMID 34473343, PMID 41671463, PMID 35713300, PMID 35622074, PMID 34013969, PMID 36734509, PMID 37162745, PMID 35244208, PMID 34658014, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 40190112, PMID 41276263, PMID 32192578, PMID 32499241, PMID 32788708, PMID 33044747, PMID 34895272, PMID 35257644, PMID 37068952, PMID 37947276, PMID 39377226, PMID 39756216, PMID 40099800, PMID 40592258, PMID 25424918, PMID 26903338, PMID 28193518, PMID 28495354, PMID 29515037, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33020485, PMID 33305842, PMID 33306989, PMID 33542052, PMID 33617777, PMID 33754144, PMID 34817414
2014 (54), 2023 (49), 2009 (38), 2016 (38), 2015 (35), 2019 (32), 2008 (31), 2017 (30), 2025 (27), 2018 (26), P30CA015704 (19), 2005 (9), P30CA033572 (9), U10CA032102 (9), UM1CA121947 (9)